Skip to main content
Quest Diagnostics

Education for Testing Fertility Patients During COVID-19

Description: Q and A video with Charles Jenkins of ReproSource Inc. and Damian Alagia, MD, of Quest Diagnostics, regarding best practices for fertility assessment according to ACOG committee opinion, with information about key fertility tests including the Ovarian Assessment Report and @Home Semen Collection.

 

Date:
Jun 11, 2020
Presenter(s):

 

  -  Alagia III, Damian P., MD, MS, MBA, FACS, FACOG, Senior

     Medical Director for Advanced Diagnostics & Women’s

     Health, Quest Diagnostics

 

  -  Charles Jenkins, Vice President, ReproSource Inc. 

Related content

Conference Presentation
Validation of a mail-in delayed semen analysis protocol developed for home collection
Publication
Highly atherogenic lipid particles are associated with preeclampsia after successful fertility treatment for obese women who have unexplained infertility
Audio Podcast
A Commitment to Women’s Health
On-Demand Webinar
The Role of Adverse Pregnancy Outcomes in Heart Disease Prevention

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.